Clinical Trial Update: Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated glecaprevir/pibrentasvir fixed-dose combination for acute hepatitis C infection, with the study completed and results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hepatitis C

Drugs mentioned

• Glecaprevir/pibrentasvir (Mavyret) (glecaprevir/pibrentasvir)

Snippet

Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Conditions: Hepatitis C Infection, HIV Infection | Phase 2 | Status: COMPLETED | Results posted: 2024-07-11